General Influenza Diagnostics Market to 2035 - Strategic Developments & Key Insights
The global influenza diagnostic market size was accounted at USD 1.79 billion in 2024, and is expected to reach around USD 3.21 billion by 2034, expanding at a CAGR of 6.01% from 2025 to 2034. The influenza diagnostic market is driven by an increasing focus on early identification to effectively manage influenza.
Influenza, commonly known as the flu, is a viral infection
primarily targeting the respiratory system, encompassing the nose, throat, and
lungs. Influenza diagnostics encompasses an array of immunoassay tests designed
to identify the presence of influenza A and B viral nucleoprotein antigens
within respiratory samples. Among the diagnostic options available are rapid
antigen testing, reverse transcription polymerase chain reaction (RT-PCR),
immunofluorescence assays, serology, and rapid molecular assays. The medical
fraternity relies on these tests to detect and categorize influenza strains
promptly, aiding in effective treatment decisions and public health management.
The continual evolution of diagnostic techniques and the ongoing research into
influenza viruses enhance the efficiency and reliability of these tests. As
healthcare providers strive to combat seasonal flu outbreaks and potential
pandemics, accurate diagnostics remain a cornerstone, enabling swift
intervention and informed medical strategies.
Recent Development
• June 2022,
BD MAX Respiratory Virus Panel (RVP, according to a statement from BD) is a new
test for the molecular diagnosis of SARS-CoV-2, Influenza A + Influenza B and
Respiratory Syncytial Virus (RSV) panel test , CE marked according to IVD
Directive 98/79/EC (Beckton Dickinson).

Comments
Post a Comment